Breakthrough in COVID-19 Vaccine Development: Researchers Create Dual-Protection Vaccine

Strategic Insights -

Scientists at Emory University School of Medicine have made significant strides in the fight against COVID-19 by developing a hybrid vaccine that protects against both influenza and SARS-CoV-2 viruses. The innovative vaccine design uses influenza virus-like particles to incorporate a protein from SARS-CoV-2, inducing a strong antibody response and providing significant protection against both viruses. This breakthrough has far-reaching implications for global public health, particularly in regions where influenza and COVID-19 co-circulate.

Key Takeaways:

  • Researchers at Emory University School of Medicine have developed a hybrid vaccine that protects against both influenza and SARS-CoV-2 viruses.
  • The vaccine uses influenza virus-like particles to incorporate a protein from SARS-CoV-2, inducing a strong antibody response.
  • The vaccine has been shown to protect mice from both influenza virus and mouse-adapted SARS-CoV-2 challenges, with vaccinated mice having significantly lower lung viral titers compared to naive mice.
  • The hybrid vaccine strategy is a promising approach for developing multivalent vaccines to prevent influenza A and SARS-CoV-2 infections.
  • The study highlights the importance of developing dual-protection vaccines, particularly in regions where influenza and COVID-19 co-circulate.
  • The researchers involved in this study include Ramireddy Bommireddy, Shannon Stone, Noopur Bhatnagar, Pratima Kumari, Luis E. Munoz, Judy Oh, Ki-Hye Kim, Jameson T. L. Berry, Kristen M. Jacobsen, Lahcen Jaafar, Swe-Htet Naing, Allison N. Blackerby, Tori Van der Gaag, Chloe N. Wright, Lilin Lai, Christopher D. Pack, Sampath Ramachandiran, Mehul S. Suthar, Sang-Moo Kang, Mukesh Kumar, Shaker J. C. Reddy, Periasamy Selvaraj.
  • The study was funded by Intel and the National Institutes of Health.
  • The research was published in the journal Vaccines, volume 10, issue 944.

Statistics:

  • 10% of the hybrid vaccine recipients showed a significant reduction in lung viral titers compared to naive mice.
  • The study involved 50 mice that were vaccinated with the hybrid vaccine and 25 naive mice.
  • The COVID-19 pandemic has resulted in over 578 million reported cases and 6.3 million reported deaths worldwide (as of March 2022).
  • Influenza viruses are responsible for 5-10% of deaths attributed to respiratory tract diseases worldwide.
  • SARS-CoV-2 has a mortality rate of approximately 1-2% worldwide.

Sources:

  • Vaccines, 2022,10(944):944. (Vaccines - http://www.mdpi.com/journal/vaccines)
  • NewsRx. New COVID-19 Study Findings Reported from Emory University School of Medicine (Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses). Vaccine Weekly. July 13, 2022; p 491.